Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-kB expression

J Endourol. 2009 Jul;23(7):1165-73. doi: 10.1089/end.2009.0035.

Abstract

Purpose: To investigate whether melatonin (MLT) treatment has any protective effect on unilateral ureteral obstruction (UUO)-induced kidney injury in rats.

Materials and methods: Six animals were included in each of the following five groups: group 1, sham operation but no treatment; group 2, unilateral ureteral ligation but no treatment; group 3, sham operation + MLT; group 4, unilateral ureteral ligation + MLT; group 5, unilateral ureteral ligation +5% ethanol (the vehicle of MLT). The injected dose of MLT was 1 mg/kg/day (intraperitoneal). MLT and vehicle were injected daily, beginning 5 days before the unilateral ureteral ligation or sham operation and until 10 days after it. At 10 days after UUO, all rats were sacrificed with high-dose ketamine. Malondialdehyde, glutathione, nitric oxide (NO), and 8-hydroxydeoxyguanosine levels and inducible NO synthase (iNOS), p38-mitogen-activated protein kinase (p38-MAPK), and nuclear factor kappa B (NF-kB) expression were studied. Histopathological examination of the obstructed kidney was also performed.

Results: UUO was accompanied by a significant increase in malondialdehyde, NO, and 8-hydroxydeoxyguanosine along with a significant decrease in glutathione levels in the kidney tissue, as well as a significant elevation in iNOS, p38-MAPK, and NF-kB expression. MLT treatment resulted in reduction of the parameters of oxidative stress and the iNOS, p38-MAPK, and NF-kB expression. MLT treatment also reduced the development of leukocyte infiltration and interstitial fibrosis in UUO rats.

Conclusions: MLT may prevent UUO-induced kidney damage in rats by reducing oxidative stress. The mechanism for this is likely mediated via reduction in the expression of iNOS, p38-MAPK, and NF-kB, since MLT reduces the activation of these pathways.

MeSH terms

  • Animals
  • Cell Movement / drug effects
  • Fibrosis / pathology
  • Glutathione / metabolism
  • Immunohistochemistry
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / enzymology
  • Kidney Diseases / etiology*
  • Kidney Diseases / pathology
  • Leukocytes / cytology
  • Leukocytes / drug effects
  • Lipid Peroxidation / drug effects
  • Male
  • Malondialdehyde / metabolism
  • Melatonin / pharmacology
  • Melatonin / therapeutic use*
  • Mitogen-Activated Protein Kinases / metabolism*
  • NF-kappa B / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / metabolism*
  • Oxidative Stress* / drug effects
  • Rats
  • Rats, Wistar
  • Ureteral Obstruction / complications*
  • Ureteral Obstruction / enzymology

Substances

  • NF-kappa B
  • Nitric Oxide
  • Malondialdehyde
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Mitogen-Activated Protein Kinases
  • Glutathione
  • Melatonin